Endocrine Abstracts

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called non-alcoholic fatty liver disease, NAFLD) is a leading cause of chronic liver disease, affecting 25% adult population worlwide. Its most advanced form is the metabolic dysfunction-associated steatohepatitis, or MASH which may progress to cirrhosis. It has no approved pharmacotherapy yet, and weight reduction is an important therapeutic option. Few studies have evaluated the effect of...